SPOP Inhibition of Endometrial Carcinoma and Its Clinicopathological Relationship
Applied Bionics and Biomechanics · 15.04.2022 · 2022 · 1-8
DOI: 10.1155/2022/5721630 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift Applied Bionics and Biomechanics, erschienen am 15.04.2022. Verfasst von Qing Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233399 Anhui, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Research Projects of Universities in Anhui Province, 512 Talent Cultivation Plan of Bengbu Medical College, National College Student Innovation and Entrepreneurship Training Program Project.
Abstract (Originalsprache)
Objective
Endometrial carcinoma (EC) ranks first in the incidence of female genital malignancies in developed countries. SPOP (speckle-type POZ protein) has changed in EC with a statistically high frequency. This research may play a crucial role in the initiation and progression of EC, ultimately leading to fresh therapeutic targets. Explore the expression of SPOP in EC; observe its effect on the proliferation, invasion, and migration of EC cells after upregulating the expression of SPOP through RNA activation.
Methods
The expression levels of SPOP protein in 150 EC tissues and 45 normal endometrial tissues were detected by immunohistochemistry and Western blotting. Analyze the relationship between SPOP expression and clinicopathological characteristics. The differences of the proliferation, migration, and invasion abilities between before and after transfection were analyzed using CCK-8 and Transwell assays.
Results
The results of immunohistochemistry and Western blotting showed the expression level of SPOP in EC tissue significantly reduced or even missed compared with normal endometrial tissue. The results of CCK-8 showed that the growth of EC significantly slowed down after the upregulating of SPOP expression. The results of the Transwell assay showed the migration and invasion abilities of EC cells were weakened after the level of SPOP was upregulated.
Conclusions
The expression level of SPOP in EC tissues is lower and related to the clinicopathological features compared with normal endometrial tissues. After upregulating the SPOP expression by RNA activation in EC cell lines, the abilities of proliferation, migration, and invasion of cells were significantly inhibited.
Autor:innen und Institutionen
- Department of Pathology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233399 Anhui, China.
- Department of Pathology, Bengbu Medical College, Bengbu, 233030 Anhui, China.
- Class 2020, Clinical Pathology, The Graduate School, Bengbu Medical College, Bengbu, 233030 Anhui, China.
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, 233030 Anhui, China.
- Class 2019, Medical Imaging Technology, The Medical Imaging School, Bengbu Medical College, Bengbu, 233030 Anhui, China.
ORCID-Profile: Huaiyong Gan
Förderung
- Natural Science Research Projects of Universities in Anhui Province
- 512 Talent Cultivation Plan of Bengbu Medical College
- National College Student Innovation and Entrepreneurship Training Program Project
Zitieren
APA
Zhu, Q., Zhang, G., Tang, M., Zheng, R., & Gan, H. (2022). SPOP Inhibition of Endometrial Carcinoma and Its Clinicopathological Relationship. Applied Bionics and Biomechanics, 2022, 1-8. https://doi.org/10.1155/2022/5721630
Vancouver
Zhu Q, Zhang G, Tang M, Zheng R, Gan H. SPOP Inhibition of Endometrial Carcinoma and Its Clinicopathological Relationship. Applied Bionics and Biomechanics. 2022;2022:1-8. doi:10.1155/2022/5721630
BibTeX
@article{Zhu2022,
author = {Zhu, Qing and Zhang, Guanghui and Tang, Mingyang and Zheng, Rumin and Gan, Huaiyong},
title = {SPOP Inhibition of Endometrial Carcinoma and Its Clinicopathological Relationship},
journal = {Applied Bionics and Biomechanics},
year = {2022},
volume = {2022},
pages = {1--8},
doi = {10.1155/2022/5721630}
}
EUVIMED